.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
US Department of Justice
Express Scripts
Moodys
Colorcon
Queensland Health
Farmers Insurance
Chinese Patent Office
Dow
Cantor Fitzgerald

Generated: September 19, 2017

DrugPatentWatch Database Preview

Septodont Company Profile

« Back to Dashboard

What is the competitive landscape for SEPTODONT, and what generic alternatives to SEPTODONT drugs are available?

SEPTODONT has eight approved drugs.

There are five US patents protecting SEPTODONT drugs.

There are thirty-one patent family members on SEPTODONT drugs in twenty countries.

Summary for Applicant: Septodont

Patents:5
Tradenames:8
Ingredients:8
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Septodont Inc
ISOCAINE HYDROCHLORIDE
mepivacaine hydrochloride
INJECTABLE;INJECTION080925-001Approved Prior to Jan 1, 1982APRXNoYes► Subscribe► Subscribe► Subscribe
Septodont
OCTOCAINE
epinephrine; lidocaine hydrochloride
INJECTABLE;INJECTION084048-002Approved Prior to Jan 1, 1982APRXNoYes► Subscribe► Subscribe► Subscribe
Septodont Inc
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
levonordefrin; mepivacaine hydrochloride
INJECTABLE;INJECTION084697-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Septodont Inc
PRILOCAINE HYDROCHLORIDE
prilocaine hydrochloride
INJECTABLE;INJECTION079235-001Sep 29, 2010RXNoYes► Subscribe► Subscribe► Subscribe
Septodont Holding
ORAVERSE
phentolamine mesylate
INJECTABLE;INJECTION022159-001May 9, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Septodont Inc
LIDOCAINE
lidocaine
OINTMENT;TOPICAL040911-001May 23, 2011ATRXNoNo► Subscribe► Subscribe► Subscribe
Septodont Holding
ORAVERSE
phentolamine mesylate
INJECTABLE;INJECTION022159-001May 9, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Septodont
OCTOCAINE
epinephrine; lidocaine hydrochloride
INJECTABLE;INJECTION084048-001Approved Prior to Jan 1, 1982APRXNoYes► Subscribe► Subscribe► Subscribe
Septodont Holding
ORAVERSE
phentolamine mesylate
INJECTABLE;INJECTION022159-001May 9, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Septodont Holding
ORAVERSE
phentolamine mesylate
INJECTABLE;INJECTION022159-001May 9, 2008RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Septodont

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,401 Local anesthetic methods and kits► Subscribe
7,261,889Local anesthetic methods and kits► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Septodont Drugs

Country Document Number Estimated Expiration
Denmark1280531► Subscribe
Spain2281418► Subscribe
Australia2001259848► Subscribe
New Zealand522930► Subscribe
Australia2003247568► Subscribe
South Africa200410093► Subscribe
Japan2006225400► Subscribe
South Africa200209811► Subscribe
European Patent Office1280531► Subscribe
Brazil0311965► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Baxter
Citi
Daiichi Sankyo
Chinese Patent Office
Mallinckrodt
Julphar
McKinsey
US Army
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot